Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Lithium’s latest drop and what it means for ASX investors
stocks
Major ASX miner remains overvalued following production update
stocks
Ahead of earnings, is Alphabet stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.90 | 33.40 | 0.37% |
| CAC 40 | 8,335.18 | 4.93 | -0.06% |
| DAX 40 | 24,875.16 | 28.47 | 0.11% |
| Dow JONES (US) | 51,839.26 | 307.16 | -0.59% |
| FTSE 100 | 10,545.92 | 21.16 | 0.20% |
| HKSE | 25,132.29 | 10.76 | -0.04% |
| NASDAQ | 25,508.07 | 12.17 | -0.05% |
| Nikkei 225 | 66,232.19 | 2,091.07 | 3.26% |
| NZX 50 Index | 13,656.03 | 40.00 | -0.29% |
| S&P 500 | 7,443.28 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,793.30 | 36.30 | 0.41% |
| SSE Composite Index | 3,864.37 | 68.09 | 1.79% |